Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jim C Hu

Showing results (41-50 of 405) with videos related to

Pageof 41
Sort By:
The New England Journal of Medicine|October 13, 2016
More on Reevaluating PSA Testing Rates in the PLCO TrialJonathan E Shoag, Sameer Mittal, Jim C Hu
The Urologic Clinics of North America|October 13, 2014
Economics of robotic surgery: does it make sense and for whom?Stephen B Williams, Kris Prado, Jim C Hu
Nature Reviews. Urology|July 1, 2026
Untangling the anterolateral periprostatic neurovasculature and its implications for nerve-sparing radical prostatectomyBehnam Nabavizadeh, Conner R Hill, Jim C Hu
The New England Journal of Medicine|September 23, 2020
Reconsidering the Trade-offs of Prostate Cancer Screening. ReplyJonathan E Shoag, Yaw A Nyame, Jim C Hu
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2016
Prostate-Specific Antigen Screening: Time to Change the Dominant Forces on the PendulumJonathan E Shoag, Peter N Schlegel, Jim C Hu
Nature Reviews. Urology|August 27, 2025
Pelvic-fascia-sparing techniques and outcomes with RARPEvan Suzman, Ang Li, Gal Wald, et al.
Nature Reviews. Urology|April 3, 2026
Evidence for metastasis-directed therapy in oligometastatic prostate cancerDorothy M Chen, Kyle A Blum, Jim C Hu
Current Opinion in Urology|November 9, 2018
Is in-office transperineal biopsy the future of prostate cancer diagnosis?Michael D Gross, Jonathan E Shoag, Jim C Hu
JAMA Oncology|September 23, 2018
Challenges in Adopting Level 1 Evidence for Multiparametric Magnetic Resonance Imaging as a Biomarker for Prostate Cancer ScreeningSoo Jeong Kim, Andrew J Vickers, Jim C Hu
Urology|April 29, 2014
Reply: To PMID 24768012Alan L Kaplan, Kuo-How Huang, Jim C Hu
Pageof 41

Showing results (41-50 of 405) with videos related to

Sort By:
Pageof 41
The New England Journal of Medicine|October 13, 2016
More on Reevaluating PSA Testing Rates in the PLCO TrialJonathan E Shoag, Sameer Mittal, Jim C Hu
The Urologic Clinics of North America|October 13, 2014
Economics of robotic surgery: does it make sense and for whom?Stephen B Williams, Kris Prado, Jim C Hu
Nature Reviews. Urology|July 1, 2026
Untangling the anterolateral periprostatic neurovasculature and its implications for nerve-sparing radical prostatectomyBehnam Nabavizadeh, Conner R Hill, Jim C Hu
The New England Journal of Medicine|September 23, 2020
Reconsidering the Trade-offs of Prostate Cancer Screening. ReplyJonathan E Shoag, Yaw A Nyame, Jim C Hu
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2016
Prostate-Specific Antigen Screening: Time to Change the Dominant Forces on the PendulumJonathan E Shoag, Peter N Schlegel, Jim C Hu
Nature Reviews. Urology|August 27, 2025
Pelvic-fascia-sparing techniques and outcomes with RARPEvan Suzman, Ang Li, Gal Wald, et al.
Nature Reviews. Urology|April 3, 2026
Evidence for metastasis-directed therapy in oligometastatic prostate cancerDorothy M Chen, Kyle A Blum, Jim C Hu
Current Opinion in Urology|November 9, 2018
Is in-office transperineal biopsy the future of prostate cancer diagnosis?Michael D Gross, Jonathan E Shoag, Jim C Hu
JAMA Oncology|September 23, 2018
Challenges in Adopting Level 1 Evidence for Multiparametric Magnetic Resonance Imaging as a Biomarker for Prostate Cancer ScreeningSoo Jeong Kim, Andrew J Vickers, Jim C Hu
Urology|April 29, 2014
Reply: To PMID 24768012Alan L Kaplan, Kuo-How Huang, Jim C Hu
Pageof 41